The Zeitgeist – 4.9.2019

3+

Every morning, we run the Narrative Machine on the past 24 hours worth of financial media to find the most on-narrative (i.e. interconnected and central) stories in financial media. It’s not a list of best articles or articles we think are most interesting … often far from it.

But for whatever reason these are articles that are representative of some sort of chord that has been struck in Narrative-world.


April 8, 2019 Narrative Map – US Equities

Source: Quid, Epsilon Theory

Here’s what does (and doesn’t) drive mortgage rates [Bank Rate]

If I were a betting man (and I am), I’d put a significant wager on the proposition that a similar mortgage primer written pre-GFC would not have mentioned the Fed at all, or at least would have had the Fed way down on the list.

Whatever you think about the Fed’s real-world power, you can’t deny the Fed’s narrative-world power.

It’s the narrative of Central Bank Omnipotence – that ALL market outcomes, good or bad, are the result of Central Bank policy – and its growth over the past decade in narrative-world is unlike anything I’ve ever seen in a professional career of studying this stuff.

The Fed is now at the top of the American Gods pantheon. They’re a classic Sun God.


Impact Partners BrandVoice: The Truth About Indexed Annuities And Market Risk [Forbes]

This is not a comment about indexed annuities and market risk, as exciting as that might be to Ken Fisher. This is a comment about the fresh hell that is Forbes Brandvoice.

Apart from having creepy eyeballs in the imagery, the point of Brandvoice is to eliminate once and for all that pesky line between editorial content and commercial content.

If you pay Forbes money, they will present your commercial advertisement exactly as if it were researched news. Not kinda sorta like researched news, but EXACTLY like researched news. It’s all just “content” to Forbes, and reporters or analysts or advertisers or marketers … they’re all just “content creators”.

To keep going with the American Gods shtick, Fiat News is a classic Trickster God.

And Forbes is their high priest.


Ecstasy and Empathy [Forbes]

MDMA is currently being assessed in two Phase III trials as a treatment for post-traumatic stress disorder. The drug’s mechanism of action consists of eliciting release of the neurotransmitters serotonin, dopamine, and noradrenaline.

Have you seen Cell, the latest Stephen King story-to-movie adaptation? It’s a really terrible movie. I also can’t stop thinking about it.

The Nudging State and Nudging Oligarchy are coming for your neurotransmitters.

I think maybe they’ve already got ’em, but I also think that we ain’t seen nothing yet.


How Can I Teach My Great-Granddaughter to Be Charitable? [New York Times]

I have an 8-year-old great-grandchild. I would like to help her develop a sense of charity. If I were to give her $40 per year to donate, how should I present the options to her, without overwhelming her?

Were I to show her images of starving Yemeni children, homeless Americans, threatened wildlife, Syrian/Central American refugees and so on, I fear she wouldn’t be able to process such a burden of information.

I think Kwame Anthony Appiah does a great job with The Ethicist column in the NYT Magazine, and his advice here is no exception.

Charity begins at home.

So does politics and investing.


More Oil & Gas Consolidation Seen in MLP Sector [24/7 Wall Street]

Upon the transaction’s close, AmeriGas will no longer be classified as an MLP and it will become a wholly owned subsidiary of UGI.

I’ve been meaning to write about the MLP-as-an-asset-class narrative for a while now, and if I don’t hurry up I won’t have anything to write about. MLPs began their life in narrative-world as a tax play (it’s literally in the name), adopted the growth/shale narrative while that was hot, and now they’re trying to become a utility/infrastructure play. A deeper dive forthcoming …


Futures subdued as investors brace for tepid earnings season [Reuters]

NEW YORK (Reuters) – The S&P 500 and the Nasdaq edged into positive territory on Monday, with gains held in check by falling industrials as investors braced for what analysts now expect to be the first quarter of contracting earnings since 2016.

As I may have mentioned once or 200 times, I am a betting man. And I would make a very substantial wager that a month from now we will see a slew of articles celebrating the “news” that 70% of companies beat Q1 earnings expectations.


3+

The Daily Zeitgeist

We Didn’t Say it WASN’T a Press Release

By Rusty Guinn | June 24, 2019 | 1 Comment

It isn’t just that cannabis always seems to make the top of the Zeitgeist. It’s why – and sometimes the answer is, “Because people are paying for it to be at the top.”

Read more

The ANDs of Asylum

By Rusty Guinn | June 23, 2019 | 0 Comments

In the midst of a complicated issue, an article from a small regional outlet manages to remind us of the power of AND in storytelling and connecting the understanding of those across the widening gyre.

Read more

Zeitgeist Narrative Map – Week of June 16 in Review

By Rusty Guinn | June 22, 2019 | 0 Comments

This is our graph of the narrative structure of the last full week in financial markets news.

Read more


That Time I Bought Blockbuster Debt

By Ben Hunt | June 20, 2019 | 0 Comments

Management is not lying to you. It’s probably a really good turn-around plan. It could probably work out fine … IF they are given enough time. But they won’t be. Particularly when it’s the second turn-around plan.

Secularly declining companies ALWAYS run out of time.

It was one of the most expensive lessons of my investing career. And worth every penny.

Read more

Democracy Dies with Dancing

By Rusty Guinn | June 18, 2019 | 0 Comments

There’s a critical, indispensable feature of a free nation we call a free press. And then there’s the meme of free press!. The latter is a pure narrative construction, and a thing well supplied in the DC market.

Read more

The Not-So-Much War

By Rusty Guinn | June 17, 2019 | 0 Comments

A tug-of-war is only a tug-of-war if both sides, y’know, are capable of pulling on the rope.

Read more

3
Leave a Reply

Please Login to comment
  Subscribe  
newest oldest
Notify of
J
Member
J

Are you aware of any government funded, paid clinical trials for Soma? Asking for a friend.

4+
Victor K
Member
Victor K

Yes! But there is no placebo arm.

1+
Mark Kahn
Member
Mark Kahn

Very excited to read your longer thoughts on MLPs as I feel I’ve lost my grasp on something I (probably falsely) believed I had a reasonable understanding of.

And, yes, especially in the last week, the “earnings are going to be terrible this quarter” story has been pushed hard to the point that you can feel that the follow-up stories of “earnings are surprisingly better than expected” are all teed up to go.

1+
DISCLOSURES

This commentary is being provided to you as general information only and should not be taken as investment advice. The opinions expressed in these materials represent the personal views of the author(s). It is not investment research or a research recommendation, as it does not constitute substantive research or analysis. Any action that you take as a result of information contained in this document is ultimately your responsibility. Epsilon Theory will not accept liability for any loss or damage, including without limitation to any loss of profit, which may arise directly or indirectly from use of or reliance on such information. Consult your investment advisor before making any investment decisions. It must be noted, that no one can accurately predict the future of the market with certainty or guarantee future investment performance. Past performance is not a guarantee of future results.

Statements in this communication are forward-looking statements. The forward-looking statements and other views expressed herein are as of the date of this publication. Actual future results or occurrences may differ significantly from those anticipated in any forward-looking statements, and there is no guarantee that any predictions will come to pass. The views expressed herein are subject to change at any time, due to numerous market and other factors. Epsilon Theory disclaims any obligation to update publicly or revise any forward-looking statements or views expressed herein. This information is neither an offer to sell nor a solicitation of any offer to buy any securities. This commentary has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Epsilon Theory recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial advisor. The appropriateness of a particular investment or strategy will depend on an investor’s individual circumstances and objectives.